PIDDs High Costs can be Mitigated, Here’s How


Published Date : Mar 29, 2016

Primary immunodeficiency diseases represents a large group of disorders that are primarily genetic in nature. These diseases directly affect a person’s resistance to diseases and therefore can seriously hamper the quality of life and in quite a few cases, life-threatening. PIDDs cannot be left undiagnosed, as they can complicate further and result in grave chronic diseases, impaired physical functions, and reduction in overall capacity to work. There are also cases where PIDD can cause permanent organ damage which could lead to death. There are even cases where the PIDD can cause the body’s immune system to seek and destroy the body’s own cells, causing serious complications. As such, treatment of PIDDs is absolutely necessary. Today, there are more than 250 rare diseases categorized under primary immunodeficiency diseases, of which a maximum number of patients require immunoglobulin treatment methods. The downside of these treatment options is the cost; the overall cost of managing PIDDs can get high quickly, quite literally disabling people and families from continuing treatment for their loved ones.

Collaboration Could Help Manage Costs
The costs of treating PIDDs can get high enough for hospitals to reconsider amount of savings a payer can make per treatment through the highly restrictive reimbursement policies surrounding PIDDs. This can be negated to a higher degree through the use of collaborative efforts between patients, insurers, and medical organizations. Communities that are set up for rare diseases can help massively in this case, especially in cases where insurers step up in the event of unpredicted issues. Another factor that needs to be considered, especially in the case of rare diseases, is the medical evidence that is required – and is sufficient – can be highly subject to change. As research and development efforts continue, the way the healthcare industry perceives these rare disorders will change.

With antibody deficiency disorders taking up at least 60% of the global market for PIDD treatments, it is no surprise that this is where research efforts will draw the most fruit. Immunoglobulin treatment can go a long way in the treatment of these diseases.